Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

March 30, 2015

Primary Completion Date

June 2, 2017

Study Completion Date

February 21, 2018

Conditions
Crohn's Disease
Interventions
DRUG

Vedolizumab

Vedolizumab intravenous injection

Trial Locations (79)

Unknown

La Jolla

Hamden

Gainesville

Inverness

Maitland

Miami

Winter Park

Macon

Suwanee

Topeka

Baton Rouge

Columbia

Boston

Ann Arbor

St Louis

Manhasset

Poughkeepsie

Winston-Salem

Cleveland

Tulsa

Portland

Germantown

Bonheiden

Brussels

Herentals

Kortrijk

Leuven

Roeselare

Vancouver

Victoria

Halifax

London

Vaughan

Hradec Králové

Kladno

Pardubice

Prague

Nice

Pessac

Reims

Lille

Saint-Étienne-de-Montluc

Lille

Nantes

Nice

Pessac

Reims

Saint-Etienne

Toulouse

Békéscsaba

Budapest

Debrecen

Gyöngyös

Gyula

Jászberény

Kistarcsa

Miskolc

Mosonmagyaróvár

Pécs

Szeged

Szekszárd

Székesfehérvár

Vác

San Giovanni Rotondo

Rozzano

San Donato Milanese

Bologna

Florence

Napoli

Padua

Roma

Rozzano

San Donato Milanese

San Giovanni Rotondo

Bialystok

Elblag

Poznan

Warsaw

Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02425111 - Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease | Biotech Hunter | Biotech Hunter